Terminated × Has results × Leukemia, Myeloid, Accelerated Phase × Clear all
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT00726830 2020-09-24

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase NA Terminated
1 enrolled 3 charts
NCT01159067 2019-06-18

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

Phase 2 Terminated
1 enrolled 4 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00295880 2017-12-28

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
12 enrolled 14 charts
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT01076270 2017-06-28

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Terminated
1 enrolled 7 charts
NCT00450983 2017-05-24

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Fred Hutchinson Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
NCT00255684 2016-11-03

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

University of Rochester

Phase NA Terminated
16 enrolled 6 charts
NCT00387426 2014-05-28

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

National Cancer Institute (NCI)

Phase 2 Terminated
14 enrolled 5 charts
NCT00608517 2014-05-20

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled 13 charts
NCT00818961 2013-12-18

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
36 enrolled 16 charts
NCT00089141 2013-05-03

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Fred Hutchinson Cancer Center

Phase 3 Terminated
151 enrolled 17 charts
NCT00827099 2012-03-23

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
5 enrolled 5 charts